Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The HDM2 protein plays an important role in regulating the stability and function of the
p53 tumor suppressor protein
. In this report, we show that the ribosomal protein L11 can interact with HDM2 and inhibit HDM2 function, thus leading to the stabilization and activation of
p53
. The inhibition of HDM2 activity by
L11
shows some similarity to the previously described activity of ARF, and expression of either ARF or
L11
can induce a
p53
response. Enhancement of the interaction between endogenous
L11
and HDM2 following treatment of cells with low levels of actinomycin-D suggests that the HDM2/
L11
interaction represents a novel pathway for
p53
stabilization in response to perturbations in ribosome biogenesis.
...
PMID:Regulation of HDM2 activity by the ribosomal protein L11. 1284 86
The gene encoding
p53
mediates a major tumor suppression pathway that is frequently altered in human cancers.
p53
function is kept at a low level during normal cell growth and is activated in response to various cellular stresses. The MDM2 oncoprotein plays a key role in negatively regulating
p53
activity by either direct repression of
p53
transactivation activity in the nucleus or promotion of
p53
degradation in the cytoplasm. DNA damage and oncogenic insults, the two best-characterized
p53
-dependent checkpoint pathways, both activate
p53
through inhibition of MDM2. Here we report that the human homologue of MDM2, HDM2, binds to ribosomal protein L11.
L11
binds a central region in HDM2 that is distinct from the ARF binding site. We show that the functional consequence of
L11
-HDM2 association, like that with ARF, results in the prevention of HDM2-mediated
p53
ubiquitination and degradation, subsequently restoring
p53
-mediated transactivation, accumulating p21 protein levels, and inducing a
p53
-dependent cell cycle arrest by canceling the inhibitory function of HDM2. Interference with ribosomal biogenesis by a low concentration of actinomycin D is associated with an increased
L11
-HDM2 interaction and subsequent
p53
stabilization. We suggest that
L11
functions as a negative regulator of HDM2 and that there might exist in vivo an
L11
-HDM2-
p53
pathway for monitoring ribosomal integrity.
...
PMID:Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. 1461 27
The ribosomal protein L11 binds to and suppresses the E3 ligase function of HDM2, thus activating
p53
. Despite being abundant as a component of the 60S large ribosomal subunit,
L11
does not induce
p53
under normal growth conditions. In search of mechanisms controlling
L11
-HDM2 interaction, we found that the induction of
p53
under growth inhibitory conditions, such as low dose of actinomycin D or serum depletion, can be significantly attenuated by knocking down
L11
, indicating the importance of
L11
in mediating these growth inhibitory signals to
p53
. We show that
L11
is not regulated by transcription or protein stability and its level remains relatively constant during serum starvation. However, serum starvation induces translocation of
L11
from the nucleolus to the nucleoplasm, where it participates in a complex with HDM2. We propose that the nucleolus acts as a barrier to prevent
L11
interacting with HDM2 during normal growth. Growth inhibition, presumably through suppression of rRNA production in the nucleolus, facilitates translocation of
L11
to the nucleoplasm, thus activating
p53
through inhibiting HDM2.
...
PMID:Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. 1515 93
The promyelocytic leukaemia (PML) tumour-suppressor protein potentiates
p53
function by regulating post-translational modifications, such as CBP-dependent acetylation and Chk2-dependent phosphorylation, in the PML-Nuclear Body (NB). PML was recently shown to interact with the
p53
ubiquitin-ligase Mdm2 (refs 4-6); however, the mechanism by which PML regulates Mdm2 remains unclear. Here, we show that PML enhances
p53
stability by sequestering Mdm2 to the nucleolus. We found that after DNA damage, PML and Mdm2 accumulate in the nucleolus in an Arf-independent manner. In addition, we found that the nucleolar localization of PML is dependent on ATR activation and phosphorylation of PML by ATR. Notably, in Pml(-/-) cells, sequestration of Mdm2 to the nucleolus was impaired, as well as
p53
stabilization and the induction of apoptosis. Furthermore, we demonstrate that PML physically associates with the nucleolar protein
L11
, and that
L11
knockdown impairs the ability of PML to localize to nucleoli after DNA damage. These findings demonstrate an unexpected role of PML in the nucleolar network for tumour suppression.
...
PMID:PML regulates p53 stability by sequestering Mdm2 to the nucleolus. 1519
The oncoprotein MDM2 associates with ribosomal proteins L5,
L11
, and L23. Both
L11
and L23 have been shown to activate
p53
by inhibiting MDM2-mediated
p53
suppression. Here we have shown that L5 also activates
p53
. Overexpression of L5 stabilized ectopic
p53
in H1299 cells and endogenous
p53
in U2OS cells. Consequently, L5 enhanced
p53
transcriptional activity and induced
p53
-dependent G1 cell cycle arrest. Furthermore, like
L11
and L23, L5 also remarkably inhibited MDM2-mediated
p53
ubiquitination. The interaction of L5 with MDM2 was also enhanced by treatment with a low dose of actinomycin D. Actinomycin D-induced
p53
was inhibited by small interference RNA against L5. By reciprocal co-immunoprecipitation, we further showed that there were at least two MDM2-ribosomal protein complexes in cells: MDM2-L5-
L11
-L23 and
p53
-MDM2-L5-
L11
-L23. We propose that the MDM2-L5-
L11
-L23 complex functions to inhibit MDM2-mediated
p53
ubiquitination and thus activates
p53
.
...
PMID:Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. 1530 43
The importance of coordinating cell growth with proliferation has been recognized for a long time. The molecular basis of this relationship, however, is poorly understood. Here we show that the ribosomal protein L23 interacts with HDM2. The interaction involves the central acidic domain of HDM2 and an N-terminal domain of L23. L23 and
L11
, another HDM2-interacting ribosomal protein, can simultaneously yet distinctly interact with HDM2 together to form a ternary complex. We show that, when overexpressed, L23 inhibits HDM2-induced
p53
polyubiquitination and degradation and causes a
p53
-dependent cell cycle arrest. On the other hand, knocking down L23 causes nucleolar stress and triggers translocation of B23 from the nucleolus to the nucleoplasm, leading to stabilization and activation of
p53
. Our data suggest that cells may maintain a steady-state level of L23 during normal growth; alternating the levels of L23 in response to changing growth conditions could impinge on the HDM2-
p53
pathway by interrupting the integrity of the nucleolus.
...
PMID:Inhibition of HDM2 and activation of p53 by ribosomal protein L23. 1531 74
Growth-dependent regulation of rRNA synthesis is mediated by TIF-IA, a basal transcription initiation factor for RNA polymerase I. We inactivated the murine TIF-IA gene by homologous recombination in mice and embryonic fibroblasts (MEFs). TIF-IA-/- embryos die before or at embryonic day 9.5 (E9.5), displaying retardation of growth and development. In MEFs, Cre-mediated depletion of TIF-IA leads to disruption of nucleoli, cell cycle arrest, upregulation of
p53
, and induction of apoptosis. Elevated levels of
p53
after TIF-IA depletion are due to increased binding of ribosomal proteins, such as
L11
, to MDM2 and decreased interaction of MDM2 with
p53
and p19(ARF). RNAi-induced loss of
p53
overcomes proliferation arrest and apoptosis in response to TIF-IA ablation. The striking correlation between perturbation of nucleolar function, elevated levels of
p53
, and induction of cell suicide supports the view that the nucleolus is a stress sensor that regulates
p53
activity.
...
PMID:Genetic inactivation of the transcription factor TIF-IA leads to nucleolar disruption, cell cycle arrest, and p53-mediated apoptosis. 1598 66
Inhibition of the MDM2-
p53
feedback loop is critical for
p53
activation in response to cellular stresses. The ribosomal proteins L5,
L11
, and L23 can block this loop by inhibiting MDM2-mediated
p53
ubiquitination and degradation in response to ribosomal stress. Here, we show that
L11
, but not L5 and L23, leads to a drastic accumulation of ubiquitinated and native MDM2. This effect is dependent on the ubiquitin ligase activity of MDM2, but not
p53
, and requires the central MDM2 binding domain (residues 51-108) of
L11
. We further show that
L11
inhibited 26 S proteasome-mediated degradation of ubiquitinated MDM2 in vitro and consistently prolonged the half-life of MDM2 in cells. These results suggest that
L11
, unlike L5 and L23, differentially regulates the levels of ubiquitinated
p53
and MDM2 and inhibits the turnover and activity of MDM2 through a post-ubiquitination mechanism.
...
PMID:Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism. 1680 2
Ribosomal proteins were recently shown to regulate
p53
activity by abrogating Mdm2-induced
p53
degradation (L23,
L11
, L5) or by enhancing
p53
translation (L26). Here, we report that a novel ribosomal protein, RPS27L (S27-like protein), is a direct p53 target. RPS27L, but not its family member RPS27, was identified as a
p53
inducible gene in a genome-wide chip-profiling study. Further characterization revealed a
p53
-dependent induction of RPS27L in multiple cancer cell models. Indeed, a consensus
p53
-binding site was identified in the first intron of the RPS27L gene and a direct binding of
p53
to this site was demonstrated both in vitro and in vivo. Characterization of a luciferase reporter driven by the RPS27L intron fragment revealed a
p53
-binding site-dependent transaction by wild-type
p53
, but not by several transactivating-deficient
p53
mutants. This transactivation was enhanced by etoposide, a DNA damaging agent that activates
p53
and was completely blocked by a dominant-negative
p53
mutant. Functionally, overexpression of RPS27L within the physiological inducible levels promoted, whereas siRNA silencing of RPS27L inhibited, apoptosis induced by etoposide. This is the first report, to our knowledge, that
p53
directly induces the expression of a ribosomal protein, RPS27L, which in turn promotes apoptosis.
...
PMID:Ribosomal protein S27L is a direct p53 target that regulates apoptosis. 1705 33
The
p53
-inhibitory function of the oncoprotein MDM2 is regulated by a number of MDM2-binding proteins, including ARF and ribosomal proteins L5,
L11
, and L23, which bind the central acidic domain of MDM2 and inhibit its E3 ubiquitin ligase activity. Various human cancer-associated MDM2 alterations targeting the central acidic domain have been reported, yet the functional significance of these mutations in tumor development has remained unclear. Here, we show that cancer-associated missense mutations targeting MDM2's central zinc finger disrupt the interaction of MDM2 with L5 and
L11
. We found that the zinc finger mutant MDM2 is impaired in undergoing nuclear export and proteasomal degradation as well as in promoting
p53
degradation, yet retains the function of suppressing
p53
transcriptional activity. Unlike the wild-type MDM2, whose
p53
-suppressive activity can be inhibited by
L11
, the MDM2 zinc finger mutant escapes
L11
inhibition. Hence, the MDM2 central zinc finger plays a critical role in mediating MDM2's interaction with ribosomal proteins and its ability to degrade
p53
, and these roles are disrupted by human cancer-associated MDM2 mutations.
...
PMID:Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. 1711 89
1
2
3
4
5
Next >>